Navigation Links
Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
Date:3/3/2008

HOUSTON - (March 2, 2008) - In an article featured on the cover of the March issue of Nature Nanotechnology, Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective. The study is included in the March 2 Advance Online Publication on Nature Nanotechnologys Web site (http://www.nature.com/nnano/index.html)

This is next generation nanomedicine, said Ferrari, the senior author. Now, were engineering sophisticated nanostructures to elude the bodys natural defenses, locate tumors and other diseased cells, and release a payload of therapeutics, contrasting agents, or both over a controlled period. Its the difference between riding a bicycle and a motorcycle.

The study - Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications - was conducted with researchers from The University of Texas M. D. Anderson Cancer Center and Rice University.

Nanotechnology offers new and powerful tools to design and to engineer novel drug delivery systems and to predict how they will work once inside the body. The field of therapeutic nanoparticles began with tiny drug-encapsulated fat bubbles called liposomes, now commonly used in cancer clinics worldwide. Targeting molecules were later added to liposomes and other nanovectors to assist in directing them to diseased cells, Ferrari said.

Getting intravenous agents to their intended targets is no easy task. Its estimated that approximately one of every 100,000 molecules of agent reaches its desired destination. Physicians are faced with the quandary of increasing the dosage, which can lead to side effects or reducing the dosage, which can limit the therapeutic benefits.

The multistage approach, according to Ferrari, is needed to circumvent the bodys natural defenses or biobarriers, which act as obstacles to foreign objects injected in the blood stream. To overcome this problem, we hypothesized and developed a multifunctional MDS comprising stage 1 mesoporous particles loaded with one or more types of stage 2 nanoparticles, which can in turn carry either active agents or higher-stage particles. We have demonstrated the loading, controlled release and simultaneous in vitro delivery of quantum-dots and carbon nanotubes to human vascular cells, the authors write.

In addition to circumventing biobarriers, Ferraris team is working on the biochemical modifications required to efficiently deliver the MDS to a specific cancer lesion. We have preliminary data that show that we can localize a payload of diagnostic agents, therapeutic agents or combination of both to target cells. Once on site, the molecules can be released in a controlled way and then the MDS will degrade in 24 to 48 hours, be transformed into orthosilicic acid and leave no trace in the body, Ferrari said.

Lead author Ennio Tasciotti, Ph.D., senior postdoctoral fellow in the NanoMedicine Research Center at the UT Health Science Center at Houston, said the proof-of-concept study would have not been possible without a multidisciplinary effort including contributions from mathematicians, physicists, engineers, chemists and biologists.

We are dealing with objects that are in the billionth of a meter size range and to study such objects we used cutting edge technologies, Tasciotti said. The characterization of the particles was performed using scanning electron and atomic force microscopy, dynamic light scattering, fluorimetry and flow cytometry. The interaction of particles with cells was studied using fluorescence and confocal microscopy as well as a series of assays intended to determine cell viability and internalization rate of the nanoparticles.


'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert  

Related medicine news :

1. UCLA, Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine
2. St. Louis University Hospital Purchases Second CyberKnife(R) System
3. Valley Baptist Health System Leveraging TITAN Technology Partners Hosting and Managed Services
4. NutriSystem and Celebrities Team Up to Benefit the American Heart Association
5. IDC X-Series DR system selected for use in leading edge RSA clinical trial application
6. Groundbreaking Sign Chi Do Stress Management System Introduced by Dr. Anne Borik Now Available to the Public
7. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
8. Medication Management Systems Names New President and COO
9. RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems
10. Brain stress system presents possible treatment
11. Plexus Systems, Inc. Names Stosz to Solutions Engineer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
(Date:1/24/2017)... GROVE, ILL. (PRWEB) , ... January 24, 2017 ... ... odor abatement solutions, announced that it has officially formed a distribution partnership with ... equipment for the industrial odor management industry. , Through the agreement, OMI Industries ...
(Date:1/24/2017)... ... ... This Saturday, January 28, the BCFA presents more than 20 local performances including ... musicians Yifan Zhou, Mara McClain & Sarah Nordlund Dennis. Local chefs and restaurants provide ... at Chinese games, crafts & more. Festivities begin at 11:00 am and end at ...
(Date:1/24/2017)... ... , ... The results from the American Cancer Society’s newest report ... cancer patients: incidents of cancer is down as is the likelihood of prostate cancer ... has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... unveiled its latest award-winning bottles, designed specifically to optimize the drinking experience for ... Agua is renowned for introducing the world’s first untouched bottled water purposed exclusively ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Choosing Wisdom-Solomon’s ... finances, friendship, marriage, leadership, gossip, prostitution, adultery, anger, and common sense. , ... Judith Coats and Dr. David Coats. In September of 1983, they flew to ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Jan. 24, 2017   Keneric Healthcare , ... cost effective patient care products, today announced their ... expand the reach of both companies by leveraging ... expertise. Angelini Pharma Inc ... now include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal). ...
(Date:1/24/2017)... , January 24, 2017 Stock-Callers.com ... Zoetis Inc. (NYSE: ZTS ), Mallinckrodt PLC (NYSE: ... ), and Diplomat Pharmacy Inc. (NYSE: DPLO ). ... for significant change in 2017 for the Generic Drugs industry, ... because of the industry,s current growth, and a speedier FDA ...
(Date:1/24/2017)... -- Laboratory Markets Limited has completed a comprehensive market ... both clinical and research laboratory settings. This study, which ... $6.8 billion and growing to $9.2 billion (CAGR of ... of mass spectrometry across more than 5,200 clinical and ... in the use of mass spectrometry in terms of ...
Breaking Medicine Technology: